期刊
JOURNAL OF LEUKOCYTE BIOLOGY
卷 102, 期 3, 页码 727-740出版社
WILEY
DOI: 10.1189/jlb.5VMR1116-458RRR
关键词
MDSC; MIF; immune suppression; PFKFB3; immune checkpoint inhibitors; tumor immunology
资金
- U.S. National Institutes of Health (NIH) [CA186661]
- NIH [CA102285, 1P30GM106396, CA149438]
- NATIONAL CANCER INSTITUTE [R01CA186661] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106396] Funding Source: NIH RePORTER
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate during pathologic conditions, such as cancer. Patients diagnosed with advanced metastatic cancers have an average survival of 12-24 mo, a survival time that hasn't changed significantly in the past 30 yr. Despite some encouraging improvements in response rates and overall survival in patients receiving immunotherapies, such as immune checkpoint inhibitors, most patients will ultimately progress. MDSCs contribute to immunotherapeutic resistance by actively inhibiting antitumor T cell proliferation and cytotoxic activity as well as by promoting expansion of protumorigenic T regulatory cells, thereby, dampening the host immune responses against the tumor. In addition, MDSCs promote angiogenesis, tumor invasion, and metastasis. Thus, MDSCs are potential therapeutic targets in cases of multiple cancers. This review focuses on the phenotypic and functional characteristics of MDSCs and provides an overview of the mono- and combinatorial-therapeutic strategies that target MDSCs with an objective of enhancing the efficacy of cancer immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据